Investigation of the Effect of the Atherogenic Index on the Therapeutic Response to Tadalafil in Patients With Vascular Erectile Dysfunction

This study aims to investigate the relationship between the atherogenic index of plasma (AIP) and the therapeutic response to daily tadalafil 5 mg treatment in patients diagnosed with vascular erectile dysfunction (VED). AIP is considered a marker of atherogenic dyslipidemia and subclinical atherosclerosis and is calculated using the formula log10 (triglycerides/HDL-C). Since vascular abnormalities play a major role in the pathophysiology of erectile dysfunction, AIP may reflect underlying vascular risk and potentially predict treatment outcomes. In this prospective observational study, patients with vascular erectile dysfunction will receive tadalafil 5 mg once daily for one month, and treatment response will be evaluated by comparing clinical parameters before and after therapy.

Inclusion Criteria:Men older than 40 years of age who have been diagnosed with vascular erectile dysfunction, have had symptoms for at least three months, have been considered suitable for tadalafil treatment, and have received tadalafil therapy for at least four weeks. \- Exclusion Criteria:Use of nitrates Uncontrolled cardiac arrhythmias Hypotension Diagnosis of hypogonadism History of major cardiovascular events within the last 6 months (including uncontrolled hypertension or severe ischemic heart disease) Severe hepatic or renal insufficiency Patients receiving hormone replacement therapy Patients diagnosed with psychogenic, neurological, hormonal, or pharmacological erectile dysfunction History of radical pelvic surgery Anatomical abnormalities of the penis History of non-arteritic anterior ischemic optic neuropathy (NAION) Retinitis pigmentosa Known hypersensitivity to tadalafil or other phosphodiesterase type-5 inhibitors Alcohol or substance abuse Use of other treatments for erectile dysfunction Unstable diabetes mellitus History of medications affecting lipid profile (such as corticosteroids or certain antidepressants) Initiation or dose modification of lipid-lowering therapy (e.g., statins, fibrates) within the last 3 months Uncontrolled thyroid dysfunction Active infection or inflammatory conditions Patients receiving active cancer treatment Inability to comply with study procedures Beck Depression Inventory score greater than 0 \-